UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000004011 |
|---|---|
| Receipt number | R000004820 |
| Scientific Title | Multicenter Phase II sequential study of S-1/Oxaliplatin (SOX) and Bevacizumab as first line therapy followed by S-1/Irinotecan (IRIS) and Cetuximab as second line in patients with metastatic colorectal cancer. : A SOBIC study |
| Date of disclosure of the study information | 2010/08/20 |
| Last modified on | 2020/08/17 12:56:55 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2010/08/06 18:10:04 | ||
| 2 | Update | 2010/08/06 18:23:08 | Condition Condition |
|
| 3 | Update | 2020/08/13 13:17:03 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code TEL Last name of contact person Last name of contact person Zip code Address Address TEL Name of primary person or sponsor Organization Post marketing survey by drug manufacture etc., specified by Japanese law. Organization Organization Address Address Tel |
|
| 4 | Update | 2020/08/17 10:10:04 | Date of IRB Last follow-up date |
|
| 5 | Update | 2020/08/17 11:55:00 | Recruitment status Date of closure to data entry Date trial data considered complete Date analysis concluded |
|
| 6 | Update | 2020/08/17 12:56:55 | URL releasing protocol Publication of results URL related to results and publications Number of participants that the trial has enrolled Results Results Results date posted Date of the first journal publication of results Baseline Characteristics Baseline Characteristics Participant flow Participant flow Adverse events Adverse events Outcome measures Outcome measures |
